New combo therapy aims to extend life for advanced kidney cancer patients
NCT ID NCT06583070
First seen Jan 31, 2026 · Last updated May 22, 2026 · Updated 16 times
Summary
This study looks at whether adding a precise type of radiation called SABR to standard targeted therapy and immunotherapy can help people with kidney cancer that has come back or spread. The goal is to improve how long the cancer stays under control and possibly extend survival. About 300 participants will be followed to compare outcomes between those who get SABR plus drugs and those who get drugs alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RADIATION THERAPY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University First Hospital
RECRUITINGBeijing, Beijing Municipality, 100034, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peking University Third Hospital
RECRUITINGBeijing, Beijing Municipality, 100091, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.